How to take Sarilumab

Sarilumab is a biologic drug currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis (ra). Biological drugs are proteins designed by humans that affect the immune system. Salirumab blocks inflammation by blocking a molecule in the immune system called interleukin-6 receptor (IL-6R). This can improve joint pain and swelling caused by rheumatoid arthritis and other symptoms caused by inflammation.

Before treatment with salivolumab, complete blood count (CBC), liver function test (LFT), lipid parameters (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and/or triglycerides), and active and latent tuberculosis infection should be tested. The recommended dose of salirumab is 200 mg subcutaneously every two weeks, as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs. It can also be used as monotherapy after discontinuation of corticosteroids, in combination with a tapering course of systemic corticosteroids in patients with polymyalgia rheumatica. In patients with rheumatoid arthritis who develop a serious or opportunistic infection, treat with salirumab until the infection is controlled, and discontinue salirumab if the patient develops neutropenia (using ANC results obtained at the end of the dosing interval), thrombocytopenia, or abnormal liver enzymes.

The patent drug of Salirutumab is a new type of drug for treating diseases. It is not yet on the market in China, and therefore it is not covered by medical insurance. Salirutumab The common dosage form of the original drug is injection, which has been marketed overseas. The European version of the specification200mg*2 per box is priced around 17,500 (The price may fluctuate due to the exchange rate). The purchase of the original drug of Salirutumab needs to be purchased through formal channels. There are currently no generic versions of Salirutumab produced in other countries.